期刊
PAIN AND THERAPY
卷 10, 期 2, 页码 1309-1330出版社
SPRINGER INT PUBL AG
DOI: 10.1007/s40122-021-00296-3
关键词
COVID-19; Novel coronavirus SARS-CoV-2; ChAdOx1 nCoV-19 (AZD1222) vaccine; Vaccination; Side effects; Cerebral venous thrombosis; Headache; International Classification of Headache Disorders; ICHD-3
Headaches attributed to vaccination with ChAdOx1 nCoV-19 (AZD1222) demonstrate a complex of symptoms including bilateral location on the forehead and temples, pressing or dull pain character, and accompanying symptoms like fatigue, chills, exhaustion, and fever. These findings have important clinical implications for the differentiation of post-vaccinal headache from other primary and secondary headaches.
Introduction The most frequently reported neurological adverse event of ChAdOx1 nCoV-19 (AZD1222) vaccine is headache in 57.5%. Several cases of cerebral venous thrombosis (CVT) have developed after vaccination. Headache is the leading symptom of CVT. For the differential diagnosis of headaches attributed to this vaccine and headaches attributed to CVT, it is of central clinical importance whether and, if so, how the phenotypes and course of these headaches can be differentiated. The study aims to examine in detail the phenotype of headache attributed to this vaccine. Methods Data on the clinical features and corresponding variables were recorded using a standardized online questionnaire in this multicenter observational cohort study. The primary outcomes of this study are the clinical features of headaches after vaccination. Findings A total of 2464 participants reported headaches after vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine. On average, headaches occurred 14.5 +/- 21.6 h after vaccination and lasted 16.3 +/- 30.4 h. A bilateral location was described by 75.8% of participants. This is most often found on the forehead (40.0%) and temples (31.4%); 50.4% reported a pressing and 37.7% a dull pain character. Headache intensity was most often severe (38.7%), moderate (35.2%), or very severe (15.5%). Accompanying symptoms were most commonly fatigue (44.8%), chills (36.1%), exhaustion (34.9%), and fever (30.4%). Conclusion Headaches attributed to COVID-19 vaccination with the ChAdOx1 nCoV-19 (AZD1222) vaccine demonstrate an extensive and characteristic complex of symptoms. The findings have several important clinical implications for the differentiation of post-vaccinal headache and other primary as well as secondary headaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据